Download Sarepta Therapeutics Announces Presentation at the 52nd

Sarepta Therapeutics Announces Presentation at the 52nd Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC) Annual Meeting
September 5, 2012 8:32 AM ET
Sep 05, 2012 (Marketwire via COMTEX) --Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based
therapeutics, announced today that the Company's therapeutic candidate AVI-7288 for the treatment of Marburg virus will be
featured in a presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual
Meeting taking place September 9-12, 2012 in San Francisco, CA.
Patrick Iversen, Ph.D., Senior Vice President of Research and Innovation at Sarepta Therapeutics, will deliver a poster
presentation titled "AVI-7288 Provides Significant Survival Benefit When Administered up to Four Days After Marburg Virus
Infection in Cynomolgus Macaques" at 11:15 a.m. PDT on Monday, September 10, 2012 during poster session 097, called New
Antiviral Agents.
The presentation will be posted on the Sarepta Therapeutics website in the "Events & Presentations" section after the session is
completed.
About Marburg Viruses
Marburg hemorrhagic fever is a severe and potentially fatal disease in humans first recognized in 1967. It is caused by an RNA
virus of the Filoviridae family and is understood to be endemic to Africa. The Marburg virus is classified as a Category A
bioterrorism agent by the Centers for Disease Control and Prevention, or CDC, and was determined to pose a material threat to
national security and public health by the Secretary of Homeland Security in 2006. Onset of the disease is often sudden, and the
symptoms include fever, chills, nausea, vomiting, chest pain and diarrhea. Increasingly severe symptoms may also include massive
hemorrhaging and multiple organ dysfunctions. There are currently no treatments for Marburg virus infection beyond supportive
care.
About Sarepta Therapeutics
Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve
and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline
includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's
most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNAbased science into transformational therapeutics for patients who face significant unmet medical needs. For more information,
please visit us at http://www.sareptatherapeutics.com/.
Sarepta Media and Investor Contact:
Erin Cox
425.354.5140
Page 1/1